Lazanda (transmucosal immediate release fentanyl [TIRF]) is now available at a 300 mcg dose strength to treat breakthrough cancer pain, Depomed has announced. This new dose will provide physicians with another titration option to improve dosing flexibility, so that patients can receive the appropriate dose for better pain management. 1
Lazanda is the only TIRF approved by the U.S. Food and Drug Administration that is delivered nasally. It is a fast-acting opioid agonist for patients who struggle swallowing due to nausea, or who experience vomiting, mucositis, oral ulcers, or dry mouth. Lazanda is indicated only for adult patients who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
In addition to the new 300 mcg dose, Lazanda is available at 100 mcg and 400 mcg strengths. All patients should initially receive a single 100 mcg spray of Lazanda, which can be titrated up to a maximum of 800 mcg depending, on the achievement of adequate analgesia.
“Helping people living with chronic and acute pain is at the forefront of everything that we do,” said Srinivas Rao, MD, PhD, Depomed’s Chief Medical Officer. “We heard from health care providers about the need for greater dosing flexibility and are pleased that we were able to meet that need with a new dose strength for Lazanda. Depomed is committed to offering medications at strengths and formulations to best address the needs of people with pain.”
RELATED: Low-dose Morphine More Effective in Treating Moderate Cancer Pain
Clinicians should be aware that Lazanda is available only through the TIRF REMS Access program, a restricted program that requires healthcare professional enrollment to prescribe Lazanda to outpatients and pharmacies.
1. Depomed releases Lazanda 300 mcg dose for treatment of breakthrough cancer pain [news release]. Newark, CA: Depomed; July 7, 2016. http://www.prnewswire.com/news-releases/depomed-releases-lazanda-300-mcg-dose-for-treatment-of-breakthrough-cancer-pain-300295134.html. Accessed July 8, 2016.